Shares of AstraZeneca PLC (NASDAQ:AZN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $89.75.
Several research firms have recently commented on AZN. Barclays upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. The Goldman Sachs Group initiated coverage on shares of AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective on the stock. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Argus upped their target price on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Finally, TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th.
View Our Latest Report on AstraZeneca
Institutional Trading of AstraZeneca
AstraZeneca Stock Up 0.4 %
Shares of NASDAQ AZN opened at $87.62 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a market cap of $271.67 billion, a PE ratio of 42.95, a P/E/G ratio of 1.63 and a beta of 0.45. The company’s fifty day simple moving average is $80.81 and its 200 day simple moving average is $74.81. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68.
AstraZeneca (NASDAQ:AZN – Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The company had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the prior year, the firm earned $1.08 EPS. The business’s revenue was up 9.1% on a year-over-year basis. As a group, sell-side analysts forecast that AstraZeneca will post 4.06 earnings per share for the current fiscal year.
AstraZeneca Cuts Dividend
The company also recently announced a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be given a dividend of $0.49 per share. The ex-dividend date is Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is currently 48.04%.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- Dividend Payout Ratio Calculator
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- What is a buyback in stocks? A comprehensive guide for investors
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.